Brooklyn Investment Group boosted its holdings in shares of HCA Healthcare, Inc. (NYSE:HCA – Free Report) by 9.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,115 shares of the company’s stock after buying an additional 93 shares during the quarter. Brooklyn Investment Group’s holdings in HCA Healthcare were worth $453,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of the business. Bangor Savings Bank boosted its holdings in HCA Healthcare by 112.5% during the second quarter. Bangor Savings Bank now owns 85 shares of the company’s stock valued at $27,000 after acquiring an additional 45 shares during the period. MFA Wealth Advisors LLC bought a new stake in shares of HCA Healthcare in the second quarter valued at about $27,000. Unique Wealth Strategies LLC bought a new stake in shares of HCA Healthcare in the second quarter valued at about $28,000. GPS Wealth Strategies Group LLC lifted its stake in shares of HCA Healthcare by 284.0% in the second quarter. GPS Wealth Strategies Group LLC now owns 96 shares of the company’s stock valued at $31,000 after buying an additional 71 shares during the period. Finally, Benjamin F. Edwards & Company Inc. bought a new stake in shares of HCA Healthcare in the second quarter valued at about $33,000. 62.73% of the stock is owned by institutional investors and hedge funds.
HCA Healthcare Price Performance
Shares of HCA stock opened at $328.95 on Wednesday. HCA Healthcare, Inc. has a 52-week low of $245.84 and a 52-week high of $417.14. The stock has a market cap of $83.32 billion, a PE ratio of 14.77, a PEG ratio of 1.25 and a beta of 1.68. The company has a debt-to-equity ratio of 48.71, a quick ratio of 1.00 and a current ratio of 1.12. The firm’s 50 day moving average price is $376.47 and its two-hundred day moving average price is $358.74.
HCA Healthcare Dividend Announcement
Insider Transactions at HCA Healthcare
In related news, SVP Phillip G. Billington sold 3,897 shares of the business’s stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $350.00, for a total value of $1,363,950.00. Following the sale, the senior vice president now directly owns 52,702 shares of the company’s stock, valued at approximately $18,445,700. The trade was a 6.89 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Michael S. Cuffe sold 8,358 shares of the business’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $385.42, for a total transaction of $3,221,340.36. Following the completion of the sale, the executive vice president now directly owns 29,678 shares in the company, valued at $11,438,494.76. This represents a 21.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 15,155 shares of company stock valued at $5,608,990 over the last three months. 1.70% of the stock is currently owned by corporate insiders.
Analyst Ratings Changes
Several equities research analysts recently weighed in on the stock. Wolfe Research upgraded shares of HCA Healthcare to a “strong-buy” rating in a research note on Thursday, August 29th. Raymond James lowered shares of HCA Healthcare from an “outperform” rating to a “market perform” rating in a research report on Friday, November 22nd. StockNews.com lowered shares of HCA Healthcare from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. UBS Group increased their price target on shares of HCA Healthcare from $405.00 to $438.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. Finally, Oppenheimer increased their price target on shares of HCA Healthcare from $390.00 to $400.00 and gave the stock an “outperform” rating in a research report on Monday, October 28th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, HCA Healthcare presently has a consensus rating of “Moderate Buy” and a consensus target price of $380.29.
Check Out Our Latest Research Report on HCA Healthcare
About HCA Healthcare
HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.
Further Reading
- Five stocks we like better than HCA Healthcare
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Cerence Up 155% in 2 Days: SoundHound AI’s Fierce Competitor
- Do ETFs Pay Dividends? What You Need to Know
- Why Warren Buffett Is Selling: A Look at His Latest Market Moves
- What is Insider Trading? What You Can Learn from Insider Trading
- Why Amazon Shares May Never Trade Below $200 Again
Want to see what other hedge funds are holding HCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HCA Healthcare, Inc. (NYSE:HCA – Free Report).
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.